Brainstorm Cell Therapeutics (BCLI) Tops Q4 EPS by 1c

Note: EPS may not be comparable

Brainstorm Cell Therapeutics (NASDAQ: BCLI) reported Q4 EPS of ($0.26), $0.01 better than the analyst estimate of ($0.27). Revenue for the quarter came in at $0 , versus $0 reported last year.

For earnings history and earnings-related data on Brainstorm Cell Therapeutics (BCLI) click here.

You May Also Be Interested In

• Delta Air Lines (DAL) Tops Q2 EPS by 3c, Beats on Revenue; Offers Guidance
• Barclays upgrades CubeSmart, cuts Public Storage on relative valuation
• Piper Sandler on FirstSun Capital Bancorp (FSUN): 'We expect shares to underperform on Friday'